In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer

Martin Behe; Karen Alt; Friederike Deininger; Patrick Bühler; Ulrich Wetterauer; Wolfgang A Weber; Ursula Elsässer-Beile; Philipp Wolf

In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer

Martin Behe, Karen Alt, Friederike Deininger, Patrick Bühler, Ulrich Wetterauer, Wolfgang A Weber, Ursula Elsässer-Beile, Philipp Wolf

Research output: Contribution to journal › Article › Research › peer-review

20 Citations (Scopus)

Abstract

Aim: The goal of the present study was to test the ¹⁷⁷Lu- labelled anti-PSMA monoclonal antibody 3/F11 (¹⁷⁷Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model. Materials and Methods: The mAb 3/FU was ¹⁷⁷Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of ¹⁷⁷Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated. Results: 3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of ¹⁷⁷Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq ¹⁷⁷Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival. Conclusion: This study indicated that ¹⁷⁷Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.

Original language	English
Pages (from-to)	55-59
Number of pages	5
Journal	In Vivo
Volume	25
Issue number	1
Publication status	Published - Jan 2011
Externally published	Yes

Keywords

Lu-DOTA-3/F11
Monoclonal antibody
Prostate cancer
PSMA
Radioimmunotherapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{c8ad23fdf3f8460cb0d88d73ec4ecc7e,

title = "In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer",

abstract = "Aim: The goal of the present study was to test the 177Lu- labelled anti-PSMA monoclonal antibody 3/F11 (177Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model. Materials and Methods: The mAb 3/FU was 177Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of 177Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated. Results: 3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of 177Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq 177Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival. Conclusion: This study indicated that 177Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.",

keywords = "Lu-DOTA-3/F11, Monoclonal antibody, Prostate cancer, PSMA, Radioimmunotherapy",

author = "Martin Behe and Karen Alt and Friederike Deininger and Patrick B{\"u}hler and Ulrich Wetterauer and Weber, {Wolfgang A} and Ursula Els{\"a}sser-Beile and Philipp Wolf",

year = "2011",

month = jan,

language = "English",

volume = "25",

pages = "55--59",

journal = "In Vivo",

issn = "0258-851X",

publisher = "International Institute of Anticancer Research",

number = "1",

}

TY - JOUR

T1 - In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer

AU - Behe, Martin

AU - Alt, Karen

AU - Deininger, Friederike

AU - Bühler, Patrick

AU - Wetterauer, Ulrich

AU - Weber, Wolfgang A

AU - Elsässer-Beile, Ursula

AU - Wolf, Philipp

PY - 2011/1

Y1 - 2011/1

N2 - Aim: The goal of the present study was to test the 177Lu- labelled anti-PSMA monoclonal antibody 3/F11 (177Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model. Materials and Methods: The mAb 3/FU was 177Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of 177Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated. Results: 3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of 177Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq 177Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival. Conclusion: This study indicated that 177Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.

AB - Aim: The goal of the present study was to test the 177Lu- labelled anti-PSMA monoclonal antibody 3/F11 (177Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model. Materials and Methods: The mAb 3/FU was 177Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of 177Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated. Results: 3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of 177Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq 177Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival. Conclusion: This study indicated that 177Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.

KW - Lu-DOTA-3/F11

KW - Monoclonal antibody

KW - Prostate cancer

KW - PSMA

KW - Radioimmunotherapy

UR - http://www.scopus.com/inward/record.url?scp=79952017967&partnerID=8YFLogxK

M3 - Article

C2 - 21282735

AN - SCOPUS:79952017967

SN - 0258-851X

VL - 25

SP - 55

EP - 59

JO - In Vivo

JF - In Vivo

IS - 1

ER -

In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer

Abstract

Keywords

UN SDGs

Other files and links

Cite this